TGFB1 and COVID-19: Importantly, incubation of NK cells from healthy donors with serum from severe COVID-19 patients at early stages after symptom onset also let to impaired NK-mediated cytotoxicity that could be reversed by pre-treating with TGF-β blocking antibodies.